Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNTA Centessa Pharmaceuticals	$17.01 -3.0%	$15.28	$9.60 ▼ $19.09	$2.35B	1.48	1.17 million shs	1.13 million shs
KROS Keros Therapeutics	$15.56 +2.6%	$14.04	$9.12 ▼ $72.37	$616.13M	1.33	456,951 shs	675,014 shs
OGN Organon & Co.	$9.42 +1.5%	$9.68	$8.01 ▼ $23.10	$2.45B	0.6	4.78 million shs	3.55 million shs
TARS Tarsus Pharmaceuticals	$57.25 +1.2%	$43.84	$25.19 ▼ $57.60	$2.42B	0.79	729,781 shs	615,773 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNTA Centessa Pharmaceuticals	-2.97%	-5.76%	+9.25%	+32.17%	+39.31%
KROS Keros Therapeutics	+2.57%	+7.46%	+7.83%	+6.79%	-66.85%
OGN Organon & Co.	+1.56%	-0.11%	-6.61%	+8.40%	-55.21%
TARS Tarsus Pharmaceuticals	+1.22%	+5.61%	+35.60%	+33.20%	+119.52%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CNTA Centessa Pharmaceuticals	2.1999 of 5 stars	3.5	1.0	0.0	0.0	1.5	2.5	0.6
KROS Keros Therapeutics	3.0508 of 5 stars	3.3	2.0	0.0	0.0	3.3	3.3	0.6
OGN Organon & Co.	4.7482 of 5 stars	3.3	2.0	1.7	3.7	3.6	1.7	2.5
TARS Tarsus Pharmaceuticals	1.9342 of 5 stars	2.5	1.0	0.0	0.0	3.6	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CNTA Centessa Pharmaceuticals	3.00	Buy	$28.10	65.20% Upside
KROS Keros Therapeutics	2.50	Moderate Buy	$30.00	92.80% Upside
OGN Organon & Co.	2.50	Moderate Buy	$18.00	91.08% Upside
TARS Tarsus Pharmaceuticals	3.00	Buy	$66.67	16.45% Upside

Current Analyst Ratings Breakdown

Latest KROS, OGN, TARS, and CNTA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	CNTA Centessa Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
8/8/2025	KROS Keros Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$25.00 ➝ $20.00
7/30/2025	CNTA Centessa Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
7/21/2025	CNTA Centessa Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00
6/10/2025	KROS Keros Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$32.00 ➝ $18.00
6/2/2025	TARS Tarsus Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$75.00
5/30/2025	KROS Keros Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$15.00
5/28/2025	CNTA Centessa Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$35.00
5/27/2025	TARS Tarsus Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$72.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CNTA Centessa Pharmaceuticals	$6.85M	332.53	N/A	N/A	$2.58 per share	6.59
KROS Keros Therapeutics	$232.84M	2.71	N/A	N/A	$17.40 per share	0.89
OGN Organon & Co.	$6.28B	0.39	$5.01 per share	1.88	$2.82 per share	3.34
TARS Tarsus Pharmaceuticals	$295.52M	8.18	N/A	N/A	$7.88 per share	7.27

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CNTA Centessa Pharmaceuticals	-$235.76M	-$1.79	N/A	N/A	N/A	N/A	-40.39%	-29.87%	11/11/2025 (Estimated)
KROS Keros Therapeutics	-$187.35M	$0.31	50.20	N/A	1.86	8.06%	2.96%	2.74%	11/5/2025 (Estimated)
OGN Organon & Co.	$864M	$2.69	3.50	2.52	0.97	11.15%	163.88%	6.99%	10/30/2025 (Estimated)
TARS Tarsus Pharmaceuticals	-$115.55M	-$2.33	N/A	N/A	N/A	-31.13%	-32.36%	-21.04%	N/A

Latest KROS, OGN, TARS, and CNTA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	CNTA Centessa Pharmaceuticals	-$0.35	-$0.38	-$0.03	-$0.38	$0.63 million	N/A
8/6/2025	Q2 2025	KROS Keros Therapeutics	-$1.14	-$0.76	+$0.38	-$0.76	$3.83 million	$0.02 million
8/6/2025	Q2 2025	TARS Tarsus Pharmaceuticals	-$0.33	-$0.48	-$0.15	-$0.48	$95.81 million	$102.66 million
8/5/2025	Q2 2025	OGN Organon & Co.	$0.94	$1.00	+$0.06	$0.56	$1.55 billion	$1.59 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CNTA Centessa Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
KROS Keros Therapeutics	N/A	N/A	N/A	N/A	N/A
OGN Organon & Co.	$0.08	0.85%	N/A	2.97%	N/A
TARS Tarsus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Latest KROS, OGN, TARS, and CNTA Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
8/6/2025	OGN Organon & Co.	quarterly	$0.02	0.9%	8/15/2025	8/15/2025	9/11/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CNTA Centessa Pharmaceuticals	0.32	10.11	10.12
KROS Keros Therapeutics	N/A	21.11	21.11
OGN Organon & Co.	11.98	1.65	1.13
TARS Tarsus Pharmaceuticals	0.22	5.26	5.21

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CNTA Centessa Pharmaceuticals	82.01%
KROS Keros Therapeutics	71.56%
OGN Organon & Co.	77.43%
TARS Tarsus Pharmaceuticals	90.01%

Insider Ownership

Company	Insider Ownership
CNTA Centessa Pharmaceuticals	7.09%
KROS Keros Therapeutics	20.60%
OGN Organon & Co.	1.96%
TARS Tarsus Pharmaceuticals	8.97%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CNTA Centessa Pharmaceuticals	200	133.91 million	124.42 million	Optionable
KROS Keros Therapeutics	100	40.62 million	32.25 million	Optionable
OGN Organon & Co.	4,000	259.97 million	254.87 million	Not Optionable
TARS Tarsus Pharmaceuticals	50	42.21 million	38.43 million	Optionable

KROS, OGN, TARS, and CNTA Headlines

Recent News About These Companies

Tarsus Pharmaceuticals, Inc. $TARS Shares Sold by Atika Capital Management LLC

3 hours ago | marketbeat.com

Russell Investments Group Ltd. Acquires 132,450 Shares of Tarsus Pharmaceuticals, Inc. $TARS

August 23 at 4:26 AM | marketbeat.com

Tarsus Pharmaceuticals, Inc. $TARS Shares Sold by Invesco Ltd.

August 20 at 3:42 AM | marketbeat.com

Lord Abbett & CO. LLC Acquires 51,714 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

August 16, 2025 | marketbeat.com

Insider Selling: Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) CEO Sells 6,000 Shares of Stock

August 15, 2025 | marketbeat.com

Lyme Disease Is Spiking. This Biotech Nears A Treatment And A Buy Point.

August 15, 2025 | msn.com

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) CEO Sells $300,000.00 in Stock

August 14, 2025 | insidertrades.com

Informed Momentum Co LLC Decreases Stock Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

August 14, 2025 | marketbeat.com

Stocks To Watch: Tarsus Pharmaceuticals Sees RS Rating Jump To 87

August 12, 2025 | msn.com

Blair William & Co. IL Sells 15,814 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

August 12, 2025 | marketbeat.com

HC Wainwright Brokers Raise Earnings Estimates for TARS

August 12, 2025 | americanbankingnews.com

Q3 EPS Forecast for Tarsus Pharmaceuticals Raised by Analyst

August 11, 2025 | marketbeat.com

Brokers Offer Predictions for TARS Q3 Earnings

August 11, 2025 | marketbeat.com

Analyst Estimates: Here's What Brokers Think Of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) After Its Second-Quarter Report

August 9, 2025 | finance.yahoo.com

FY2027 Earnings Forecast for TARS Issued By HC Wainwright

August 9, 2025 | marketbeat.com

Tarsus Pharmaceuticals (NASDAQ:TARS) Stock Price Up 13.4% - What's Next?

August 8, 2025 | marketbeat.com

Earnings To Watch: Tarsus Pharmaceuticals Inc (TARS) Reports Q2 2025 Result

August 7, 2025 | finance.yahoo.com

Tarsus targets 95,000–100,000 bottles for Q3 2025 amid accelerated XDEMVY launch momentum

August 7, 2025 | msn.com

Tarsus Pharmaceuticals, Inc. (TARS) Q2 2025 Earnings Call Transcript

August 7, 2025 | seekingalpha.com

Tarsus Pharmaceuticals, Inc. 2025 Q2 - Results - Earnings Call Presentation

August 7, 2025 | seekingalpha.com

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates

August 6, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KROS, OGN, TARS, and CNTA Company Descriptions

Centessa Pharmaceuticals NASDAQ:CNTA

$17.01 -0.52 (-2.97%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$17.47 +0.46 (+2.73%)

As of 08/22/2025 07:57 PM Eastern

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

Keros Therapeutics NASDAQ:KROS

$15.56 +0.39 (+2.57%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$15.47 -0.09 (-0.58%)

As of 08/22/2025 06:57 PM Eastern

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Organon & Co. NYSE:OGN

$9.42 +0.14 (+1.51%)

Closing price 08/22/2025 03:59 PM Eastern

Extended Trading

$9.44 +0.02 (+0.16%)

As of 08/22/2025 05:06 PM Eastern

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Tarsus Pharmaceuticals NASDAQ:TARS

$57.25 +0.69 (+1.22%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$58.04 +0.80 (+1.39%)

As of 08/22/2025 07:09 PM Eastern

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time